Last reviewed · How we verify
Terlipressin plus standard care
Terlipressin is a synthetic analogue of vasopressin that acts as a potent vasoconstrictor.
Terlipressin is a synthetic analogue of vasopressin that acts as a potent vasoconstrictor. Used for Hepatorenal syndrome.
At a glance
| Generic name | Terlipressin plus standard care |
|---|---|
| Also known as | terlipressin infusion plus routine care |
| Sponsor | Shanghai Zhongshan Hospital |
| Drug class | Vasopressin analogue |
| Target | Vasopressin receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
It works by stimulating vasopressin receptors, leading to increased blood pressure and reduced portal blood flow. This mechanism is particularly useful in treating conditions like hepatorenal syndrome.
Approved indications
- Hepatorenal syndrome
Common side effects
- Hypotension
- Headache
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
- Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial) (NA)
- National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem Cell Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patient- Phase-II Trial (PHASE2)
- National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem-Cell (MSC) Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patients - Phase-III Trial (PHASE3)
- HRS-AKI Treatment With TIPS in Patients With Cirrhosis (NA)
- A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites (PHASE2)
- Comparison of Bolus Versus Continuous Infusion of Terlipressin Cirrhotic Patients With Septic Shock. (NA)
- Microcirculation Recruitment Using Albumin 20% and Terlipressin in Septic Patients (PHASE1)
- Effects of Terlipressin on Renal Perfusion in Patients With Septic Shock (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Terlipressin plus standard care CI brief — competitive landscape report
- Terlipressin plus standard care updates RSS · CI watch RSS
- Shanghai Zhongshan Hospital portfolio CI